Futibatinib (TAS-120)

(Lytgobi®)

Lytgobi®

Drug updated on 4/18/2024

Dosage FormTablets (oral; 4 mg)
Drug ClassKinase inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated, with no liability accepted for reliance on it. Learn more.

  • Futibatinib (TAS-120), also known as Lytgobi, is indicated for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.
  • Information about this drug was derived from a single study, which is a Randomized Controlled Trial.
  • In terms of effectiveness compared to other treatments for the same condition, futibatinib demonstrated significant antitumor activity in FGFR-altered tumors. It showed consistent responses across several patient subgroups including heavily pretreated patients and older adults.
  • The comparison of safety profiles revealed that while futibatinib incurs a notable occurrence of grade 3 adverse events such as hyperphosphatemia and fatigue among others; these were manageable, leading to permanent discontinuation in only 2% of cases, indicating a favorable safety profile with manageable adverse events.
  • Quality of life maintenance throughout treatment with futibatinib indicates that despite its side effects, it does not detrimentally affect patient well-being, reflecting an ability not just to prolong life but to maintain its quality as well.
  • The assessment is limited by the absence of direct comparative data with other drugs within the same therapeutic domain, necessitating the analysis of additional literature to fully contextualize these findings within the broader treatment landscape for intrahepatic cholangiocarcinoma.

Product Monograph / Prescribing Information

Document TitleYearSource
Lytgobi (futibatinib) Prescribing Information.2022Taiho Oncology, Inc., Princeton, NJ

Randomized Controlled Trials

Document TitleSex DistributionYearSource
Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma
6Subjects
F: 0%
M: 100%
2023The New England Journal Of Medicine

Sex Distribution:

F:0%
M:100%
6Subjects

Year:

2023

Source:The New England Journal Of Medicine